Bintrafusp alfa with cCRT followed by bintrafusp alfa versus placebo with cCRT followed by durvalumab in patients with unresectable stage III NSCLC: A phase 2 randomized study

Authors

Everett E Vokes, University of Chicago
Clifford G Robinson, Washington University School of Medicine in St. Louis
et al.

Journal

Journal of Thoracic Oncology

Publication Date

2-1-2024

Volume

19

Issue

2

First Page

285

Last Page

296

Document Type

Open Access Publication

DOI

10.1016/j.jtho.2023.09.1452

Rights and Permissions

Vokes EE, Mornex F, Sezer A, Cheng Y, Fang J, Baz DV, Cil T, Adjei AA, Ahn MJ, Barlesi F, Felip E, Garon EB, Audhuy F, Ito R, Sato M, Eggleton SP, Martin CM, Reck M, Robinson CG, Paz-Ares L. Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study. J Thorac Oncol. 2024 Feb;19(2):285-296. doi: 10.1016/j.jtho.2023.09.1452. Copyright 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).

Recommended Citation

Vokes, Everett E; Robinson, Clifford G; and et al., "Bintrafusp alfa with cCRT followed by bintrafusp alfa versus placebo with cCRT followed by durvalumab in patients with unresectable stage III NSCLC: A phase 2 randomized study." Journal of Thoracic Oncology. 19, 2. 285 - 296. (2024).
https://digitalcommons.wustl.edu/oa_4/5838

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.